CSIMarket
 
Roivant Sciences Ltd   (ROIV)
Other Ticker:  
 
 
Price: $9.8700 $-0.27 -2.663%
Day's High: $10.21 Week Perf: -4.08 %
Day's Low: $ 9.85 30 Day Perf: -13.8 %
Volume (M): 5,773 52 Wk High: $ 13.24
Volume (M$): $ 56,977 52 Wk Avg: $10.08
Open: $10.15 52 Wk Low: $6.59



 Market Capitalization (Millions $) 8,335
 Shares Outstanding (Millions) 844
 Employees -
 Revenues (TTM) (Millions $) 123
 Net Income (TTM) (Millions $) 4,353
 Cash Flow (TTM) (Millions $) 5,144
 Capital Exp. (TTM) (Millions $) 3

Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company that focuses on developing innovative therapeutics for various diseases and conditions. The company's goal is to rapidly bring treatments to patients by leveraging emerging technologies and data-driven approaches. Roivant Sciences operates through subsidiary companies, known as Vants, each dedicated to a specific therapeutic area or technology platform. These Vants conduct research and development, clinical trials, and commercialization efforts for their respective areas. Roivant Sciences aims to address unmet medical needs and improve patient outcomes by bringing new and effective therapies to market.


   Company Address: 7th Floor London 0
   Company Phone Number: 400 3347   Stock Exchange / Ticker: NASDAQ ROIV
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Roivant Sciences Ltd

Roivant Sciences Ltd Reveals Unprecedented Triumph: Unveils Unbelievable Results from Breakthrough Study over Oct-Dec 20232.

The stock market has been abuzz with excitement as Roivant Sciences Ltd, a leading pharmaceutical company, recently announced its impressive financial results for the third quarter ended December 31, 2023. With a remarkable revenue advance of 117.804% year on year, reaching $37.14 million, the company has turned its fortunes around and posted an impressive income per share of $6.03.
This significant improvement in earnings per share becomes even more impressive when compared to the prior quarter, where earnings per share turned positive from $-0.40 to $6.03. Additionally, revenue saw a surge of 0.105% from $37.10 million, showcasing the company's continued growth and success.

Clinical Study

Immunovant's Batoclimab Shows Promising Efficacy in Graves Disease: Initial Phase 2 Results Exceed Expectations

Published Wed, Dec 20 2023 9:30 PM UTC

Immunovant, a clinical-stage immunology company, has reported highly encouraging results from the initial cohort of patients in a 24-week Phase 2 clinical trial for batoclimab, a potential breakthrough therapy for Graves disease. The results of this trial have surpassed expectations, with response rates exceeding 50%. This achievement represents a significant advancement in ...

Merger and Acquisition

Roivant's Acquisition of Telavant Enhances Roche's Enteric Disease Portfolio: A New Era for Inflammatory Bowel Disease Treatment

Published Thu, Dec 14 2023 2:01 PM UTC


BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 - In a groundbreaking move, Roivant (Nasdaq: ROIV) announced today the successful completion of the long-awaited acquisition of Telavant by Roche (SIX: RO, ROG; OTCQX: RHHBY) for a staggering upfront payment of approximately $7.1 billion. This strategic deal grants Roche exclusive rights for RVT-310...

Clinical Study

IMVT-1402: Transforming the Landscape of Autoimmune Disease Treatment with Best-in-Class Potential

Published Tue, Nov 28 2023 12:00 PM UTC

Roivant's IMVT-1402 Demonstrates Best-in-Class Potential in Phase 1 Clinical Trial, Potentially Revolutionizing Treatment for Autoimmune Diseases
Immunovant, Inc. (Nasdaq: IMVT), a leading clinical-stage immunology company dedicated to revolutionizing treatment options for autoimmune diseases, has recently released positive initial results from a Phase 1 clinical trial o...

Clinical Study

Disappointing Phase 2 Results of Oral Brepocitinib in Lupus Highlight Roivant's Revenue Growth Struggle

Published Mon, Nov 27 2023 1:01 PM UTC



In a recent development, Roivant and Priovant announced that their Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus failed to meet its primary endpoint. Despite this setback, Roivant Sciences Ltd, the parent company of Roivant and Priovant, reported a substantial revenue increase in the third quarter of 2023. However...






 

Roivant Sciences Ltd's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com